Annual Combined Mammography and Tomosynthesis Screening: Is It Really Cost-Effective?

Abstract

Examining the comparative effectiveness of adding tomosynthesis to mammography screening in the United States would help key stakeholders, including physicians and policy makers, guide shared decision-making and recommendations for routine breast cancer screening. More robust data from U.S.-based longitudinal observational studies, clinical trials, or both are needed, along with the use of validated microsimulation models, before clinical- and cost-effectiveness of tomosynthesis screening versus mammography screening can be fully characterized.